DDInter1666 DDInter1925
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Sildenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Sildenafil {u} (Compound) downregulates {v} (Gene) CYCS
CYCS {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Sildenafil {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Sildenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Sildenafil {u} (Compound) downregulates {v} (Gene) CYCS
CYCS {u} (Gene) is regulated by {v} (Gene) ADCK3
ADCK3 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Sildenafil {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Sildenafil {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Sildenafil {u} (Compound) causes {v} (Side Effect) Retinal vein occlusion
Retinal vein occlusion {u} (Side Effect) is caused by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Sildenafil {u} (Compound) resembles {v} (Compound) Udenafil
Udenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Sildenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Sildenafil (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Vemurafenib (Compound)
Sildenafil (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may lead to a major life threatening interaction when taken with Vemurafenib
Sildenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Sildenafil (Compound) downregulates CYCS (Gene) and CYCS (Gene) is regulated by ADCK3 (Gene) and ADCK3 (Gene) is upregulated by Vemurafenib (Compound)
Sildenafil (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Sildenafil (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Sildenafil (Compound) causes Retinal vein occlusion (Side Effect) and Retinal vein occlusion (Side Effect) is caused by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Sildenafil (Compound) resembles Udenafil (Compound) and Udenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may lead to a major life threatening interaction when taken with Vemurafenib